The particulars: identity confirmation by mass spectrometry · aspartimide formation · a GLP-1 receptor agonist.
The comparison I want does not seem to exist anywhere in a form I can evaluate.
I have read the arguments for each and they do not engage with each other.
So which one, and on what grounds?
Answer first: peptide mapping is the test that earns its cost exactly when mass spectrometry on the intact molecule is uninformative, which is more often than people expect.
The workflow: reduce and alkylate any disulfides, digest with a specific protease — trypsin cleaving after lysine and arginine is the usual choice — separate the fragments by reverse-phase chromatography, and identify each by mass.
| Component | Typical share | Counted in purity? | Counted in content? |
|---|---|---|---|
| Target peptide | 88–94 % | Yes, as main peak | Yes |
| Related impurities | 1–3 % | Yes, as other peaks | No |
| Counter-ion (TFA or acetate) | 2–8 % | No | No |
| Residual water | 2–6 % | No | No |
| Bulking agent, if present | 0–40 % | No | No |
The relevant detail is that for a short peptide, trypsin may produce too few fragments to be useful. Chymotrypsin, Glu-C or a combination gives better coverage on sequences with few basic residues.
D-amino-acid substitutions being mass-identical is the structural reason intact mass cannot detect them and mapping plus fragmentation can.
A missing expected fragment is as informative as an unexpected one.
edited 23 Mar 2025 by mz_4113 — tightened the wording; no substantive change
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe relevant limitation is that a mass-neutral substitution has the same molecular weight as the correct residue and can co-elute under a routine gradient.
Sequence coverage is the headline quality metric. Anything below about ninety-five per cent leaves regions unexamined, and the unexamined regions are where a problem could sit undetected.
Disulfide scrambling gives an unchanged intact mass with different connectivity. Non-reduced mapping — digesting without reducing first — is how the correct pairings are confirmed.
The caveat is that a map confirms sequence and says nothing about content, sterility or endotoxin.
Commission it on a first lot from a new supplier, not on every lot.
The short version: enzymatic digestion, chromatographic separation of the fragments, mass identification of each, and a comparison against the theoretical map.
A D-amino-acid substitution has an identical molecular weight to its L counterpart. It is invisible to intact mass, usually invisible to a routine gradient, and detectable by mapping combined with tandem fragmentation or by chiral analysis.
More usefully, missed cleavages are normal and expected; a map with a moderate number of them is a normal map, not a failed one.
Non-reduced peptide mapping is the accepted approach to confirming disulfide connectivity.
Ask for the coverage figure with any map. Without it the result is not interpretable.
On the detail: this is the most informative single test available for a peptide identity question and it is rarely on a research-grade certificate.
The result is compared against the theoretical digest of the claimed sequence. A fragment at an unexpected mass localises a problem to a few residues; a missing expected fragment does the same from the other direction.
Peptide mapping is a compendial identity method for peptide and protein products and is specified in the relevant pharmacopoeial general chapters.
Mapping is for mass-neutral problems. That is when it earns its cost.
Answering this needs to know whether a mass-neutral substitution is plausible for the sequence, since that is the case mapping is for.
Cost is the practical objection. Mapping costs several times a purity assay, which is why it belongs on a first lot from a new supplier rather than on every lot.
Trypsin cleaving C-terminal to lysine and arginine, except before proline, is the standard specificity and is what makes a theoretical digest predictable.
Coverage below about ninety-five per cent leaves real gaps, and the reported coverage figure should always accompany the conclusion.
Non-reduced mapping is how you confirm disulfide pairings.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.